As an Assistant Professor of Medicine within the Division of Hematology/Oncology at CUIMC, Dr. McGuinness specializes in the care of patients with breast cancer or who are at high risk of developing breast cancer. She is currently involved in patient care, clinical research, and education. Her research interests include the evaluation of novel imaging-based tools to refine breast cancer risk prediction and to predict which patients receive benefit from breast cancer therapies. Dr. McGuinness also serves as the principal investigator for multiple clinical trials at CUIMC that evaluate novel treatments for patients with breast cancer. She is actively involved in the SWOG Cancer Research Network, and serves as a member of the SWOG Prevention and Epidemiology Committee.
Dr. McGuinness received her bachelor of arts in Biology magna cum laude from Williams College, and her medical degree with Honor from Baylor College of Medicine, where she was elected to the Gold Humanism Honor Society. She completed both her Internal Medicine residency and Hematology/Oncology fellowship at Columbia University Irving Medical Center (CUIMC). During her fellowship, she served as Chief Fellow and was awarded the inaugural Marc L. Citron, MD, Young Investigator Award in Breast Cancer from the Conquer Cancer Foundation and American Society of Clinical Oncology, as well as multiple merit awards through the American Society of Clinical Oncology and the American Association for Cancer Research. She also completed a Postdoctoral Research Fellowship in Biomedical Informatics at CUIMC.
|Breast Cancer||Decreasing Chemotherapy for HER2 Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy|
|Breast Cancer||Study of T-DM1 in Combination with Tucatinib for Patients with HER2-Positive Breast Cancer|
|Breast Cancer||Study of RLY-2608 in Patients with Breast Cancer|
|Breast Cancer||Study of Niraparib in Patients Who Have Been Previously Treated for Breast Cancer|
|Breast Cancer||Study of GLSI-100 in Female Patients with Breast Cancer|
|Breast Cancer||Study of Imprime PGG and Pembrolizumab (Keytruda) in Patients with Metastatic Breast Cancer (mBCA)|